ERBB2 and adenocarcinoma: HER2 inhibition in combination with cisplatin-based chemotherapy has been demonstrated to significantly improve response rate and overall or progression-free survival in patients with adenocarcinoma of the gastro-esophageal junction or the stomach who over-express HER2 [7].